Clearside Biomedical plunges after filing for Chapter 11 bankruptcy

Clearside Biomedical,

24/11/2025 15:22

Updates

** Shares of drug developer Clearside Biomedical CLSD.O slide 68.7% to $0.85

** Co files for Chapter 11 bankruptcy protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing

** Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago

** In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction

** As part of Chapter 11 process, co plans to pursue an auction and sale of assets under Section 363 of U.S. Bankruptcy Code

** Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July

** Including session's move, CLSD stock down 94% YTD

** Shares on track for lowest level since listing in 2024

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))